GLP-1 Average Weight Loss Per Month: What the Evidence Actually Shows (2026)

Updated October 2026 — refreshed with the latest head-to-head trial data and new real-world research on how much weight people actually lose on GLP-1 therapy.

Most adults on GLP-1 therapy lose roughly 1–2% of their body weight per month during the active phase of treatment — about 4–8 pounds per month for many patients — with a slower first month and a gradual leveling-off after a year or more. In the landmark STEP 1 trial, weekly semaglutide 2.4 mg produced an average total loss of 14.9% of body weight over 68 weeks; in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine, tirzepatide averaged 20.2% over 72 weeks versus 13.7% for semaglutide. Real-world averages run meaningfully lower, mostly because of inconsistent dosing and early discontinuation — which is exactly why the structure around the medication matters as much as the medication itself.

This guide walks through what the monthly numbers actually look like, why your pace may differ from a clinical trial, and how a physician-supervised weight management program is designed to keep progress steady and safe.

What the clinical trials actually show

The best available evidence comes from large randomized trials of the two GLP-1–based medications that are FDA-approved for chronic weight management: semaglutide (Wegovy) and tirzepatide (Zepbound). In STEP 1, adults with obesity taking weekly semaglutide 2.4 mg alongside lifestyle support lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. In SURMOUNT-5, the first large head-to-head comparison, tirzepatide produced an average 20.2% loss (about 50 pounds) over 72 weeks versus 13.7% (about 33 pounds) with semaglutide.

Spread across the full trial period, those totals work out to very roughly 0.8–1.3% of body weight per month on average — but weight loss on these medications is not linear. The curve is shallow in the first month while the dose is being titrated, steepest between roughly months two and nine, and flattens as the body approaches a new set point. For a 220-pound patient, the steep middle phase often looks like 4–9 pounds per month; for a smaller-framed patient, the same healthy percentage translates to fewer pounds. Comparing raw pounds with someone else is one of the least useful things you can do on this kind of program.

Why real-world results are usually lower than trial results

Outside of clinical trials, average weight loss is smaller — not because the medications work differently in the real world, but because people take them differently. A 2025 Cleveland Clinic study of 7,881 adults, published in Obesity, found that patients who stayed on treatment for a full year lost an average of 11.9% of their body weight — while those who stopped within three months lost just 3.6%. More than half of patients discontinued within the year, most often because of cost, insurance coverage, side effects, or supply problems, and more than 80% never reached the higher maintenance doses used in trials. Patients who did continue at higher maintenance doses lost 13.7% on semaglutide and 18.0% on tirzepatide — essentially matching the trials.

The practical takeaway: the single strongest predictor of your monthly average is not which month you're in. It's whether you stay on a well-managed protocol long enough for the medication to do its work, with side effects addressed early rather than endured until you quit.

A realistic month-by-month timeline

Most patients who respond to GLP-1 therapy follow a recognizable arc, even though the exact numbers vary person to person.

Month 1 is the foundation month. Starting doses are intentionally low to let your body adjust, so expect modest movement on the scale — commonly 2–4 pounds — alongside the first clear changes in appetite: smaller portions feel sufficient, and late-night or stress-driven eating quiets down. A slow first month is not a sign the medication isn't working.

Months 2–3 are when most people see momentum build. As the dose is titrated upward under provider guidance, monthly losses of 4–8 pounds are common, and the behavioral effects — reduced "food noise," easier portion control — become more established.

Months 3–9 are typically the steepest stretch of the curve. Losses of 1–2% of body weight per month are realistic here, and this is also when habits built around the medication (protein intake, movement, sleep) compound the result. Short plateaus can appear and usually resolve with adjustments your provider can make.

Months 9–18 bring deceleration — by design. As total loss approaches the 10–20% range seen in trials, monthly numbers shrink and eventually stabilize. This phase is about consolidating a new baseline, not chasing the early pace. In our view, a patient who loses 12% of body weight and keeps it off has had a far better outcome than one who loses 18% quickly and regains it.

What shapes your monthly pace

Five factors explain most of the person-to-person variation. Starting weight matters because percentage loss translates to more pounds on a larger frame. The specific medication matters — our guide to semaglutide vs. tirzepatide covers the head-to-head evidence in detail. Dose and consistency matter enormously, as the Cleveland Clinic data shows; dosing decisions always belong to your prescriber, and a program that monitors you closely can address nausea or other side effects before they derail treatment. Metabolic context — insulin resistance, PCOS, thyroid function, other medications — can change the slope, which is why a proper intake includes your full history and, where appropriate, lab review. And lifestyle still counts: these medications reduce appetite, but adequate protein, hydration, resistance exercise and sleep determine how much of the weight lost is fat rather than muscle.

Plateaus — and what happens if you stop

Plateaus are a normal feature of medically supported weight loss, not a failure. The honest evidence on discontinuation is also worth knowing before you start: in the STEP 1 extension study, published in Diabetes, Obesity and Metabolism, participants who stopped semaglutide regained about two-thirds of their lost weight within a year. Obesity medicine increasingly treats these medications as long-term therapy for a chronic condition rather than a short sprint — and any decision to continue, taper, or stop belongs in a conversation with a licensed provider, never a calendar deadline. If you're weighing how long treatment typically lasts, our guide to how quickly GLP-1 therapy starts working covers the early phase in more depth.

Supporting your progress between appointments

The patients who do best treat the medication as one component of a larger system. Prioritize 20–30 grams of protein per meal to protect lean muscle while eating less. Stay ahead of hydration — GLP-1s slow gastric emptying, and mild dehydration is behind much of the fatigue and dizziness patients report. Build movement you'll actually repeat, even ten-minute walks. And keep your follow-up schedule: titration timing, side-effect management, and plateau troubleshooting are where supervised programs earn their keep. For a candid look at where IV hydration fits — and doesn't — alongside a weight program, see our piece on metabolism IV therapy and weight loss.

How a physician-supervised program works in Los Angeles

A legitimate medical weight management program starts with screening, not a sale. At IV Glow Bar, serving Beverly Hills, West Hollywood and the surrounding Westside from our San Vicente Boulevard clinic — with concierge visits available — that means a health intake review, a conversation about your history and goals, and eligibility determined by a licensed provider before any treatment is considered (our guide to BMI criteria for GLP-1 therapy explains the clinical thresholds). From there, the program is built around supervision: structured follow-ups, dose management through your provider, and support for the nutrition and recovery pieces that determine whether monthly numbers hold. If you'd like to find out whether a supervised program is right for you, you can book a consultation or call or text 310-579-6779.

Frequently asked questions

Is it normal to lose only a few pounds in the first month on a GLP-1?

Yes. Starting doses are deliberately low while your body adjusts, so a 2–4 pound first month is typical and expected. Most patients see their pace pick up in months two and three as the dose is titrated.

How much weight do you lose in 3 months on GLP-1 therapy?

Many patients lose roughly 5–8% of their starting body weight in the first three months — for a 200-pound person, about 10–16 pounds — though the range is wide and depends on medication, dose, and consistency.

Does weight loss slow down after 6 months?

Usually, yes — and that's expected. The loss curve is steepest in the early-to-middle months and flattens as your body approaches a new, lower set point. Slower months later in treatment still contribute to the overall result.

Will I regain the weight if I stop taking a GLP-1?

The evidence says regain is common: in the STEP 1 extension study, participants regained about two-thirds of lost weight within a year of stopping. That's a reason to think of treatment as long-term chronic care and to make any change in consultation with your provider.

Is losing more per month always better?

No. Very rapid loss raises the risk of muscle loss, fatigue, and nutritional gaps. A steady 1–2% of body weight per month, with adequate protein and strength activity, tends to produce results that last.

Care at IV Glow Bar is delivered by our registered nurse under the supervision of our medical director, Dr. Groke, who oversees every weight management protocol. Meet our licensed providers.

Medical disclaimer: This article is for general information only and is not medical advice. These services are not suitable for everyone; a health intake review is required, and treatment decisions are made by a licensed provider after clinical evaluation. Individual response varies, and no outcome is guaranteed.